Advertisement
The Essential Resource for the Medical Design Engineering Community
Subscribe to MDT Magazine All

Calibra Gains FDA Clearance to Market Finesse™ Insulin Patch-Pen for Three-Day Use With Novolog®

July 26, 2010 7:35 am | by Bio-Medicine.Org | News | Comments

REDWOOD CITY, Calif. , July 26 /- Calibra Medical announced today it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Finesse™ insulin patch-pen for up to three-day use with Novo Nordisk's Novolog ® rapid acting insulin. Combining the...

TOPICS:

Circle Biologics® Introduces Innovation in Medical Devices

July 26, 2010 7:35 am | by Bio-Medicine.Org | News | Comments

MINNEAPOLIS , July 26 /- Circle Biologics®, Inc. has announced a technological break-through in regenerative medicine – its Autologous Platelet Concentrator Platform (APC™).  This innovative single device platform is the first of its kind to incorporate both...

TOPICS:

Brainlab Offers Real-Time Monitoring for IGRT

July 26, 2010 7:34 am | by Bio-Medicine.Org | News | Comments

WESTCHESTER, Ill. , July 26 /- Brainlab announced the availability of ExacTrac® Infrared Monitoring, an add-on device to existing treatment machines for monitoring patient positioning during radiation therapy treatments, at the American Association of Physicists in Medicine (AAPM)...

TOPICS:
Advertisement

Medical Device Safety Tip: Air or Electric Dermatome Instruments

July 26, 2010 7:31 am | by U.S. Food & Drug Administration | News | Comments

FDA has received several reports of patients suffering lacerations when undergoing skin grafting procedures with air- or electric-powered Dermatome surgical instruments made by Zimmer, Inc. In one report, the device cut through to the bone and the...

TOPICS:

Orthovita gets clearance on collagen facility

July 26, 2010 4:45 am | by The Associated Press | News | Comments

Orthovita Inc. said Monday it received regulatory approval for a facility where it will process collagen used in Vitagel, a product used to control bleeding during surgery.The company said the Food and Drug Administration cleared a supplement for the new facility, which is located in Malvern,...

Boston Scientific Launches Neuroform EZâ„¢ Stent System in U.S. and Europe

July 26, 2010 4:34 am | by Boston Scientific | News | Comments

Company expands market-leading family of neurovascular stents

TOPICS:

Onyx Pharmaceuticals Announces Positive Top-Line Carfilzomib Data From Phase 2b Study

July 26, 2010 3:36 am | by Bio-Medicine.Org | News | Comments

EMERYVILLE, Calif. , July 26 /- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced positive top-line results from the Phase 2b 003-A1 study of single-agent carfilzomib, a selective, next generation proteasome inhibitor, in patients with relapsed and refractory multiple myeloma....

TOPICS:

Delcath Systems Announces Second Quarter Progress Report Conference Call

July 26, 2010 3:36 am | by Bio-Medicine.Org | News | Comments

NEW YORK , July 26 /- Delcath Systems, Inc. (Nasdaq: DCTH ) announced today that it will host a conference call to discuss its second quarter results and recent corporate developments on Thursday, July 29, 2010 at 4:30pm, ET . Eamonn Hobbs , President and Chief Executive Officer, and...

TOPICS:
Advertisement

Harco Partners With ConMediSys to Deliver Patient Safety and Equipment Integrity

July 26, 2010 3:36 am | by Bio-Medicine.Org | News | Comments

TEMPE, Ariz. , July 26 /- Harco Metal Products (Harco), an industry leader in tube fabrication, systems integration, and seamless, cost effective manufacturing, announced today the contract to manufacture MediGLIDERâ„¢ products for ConMediSys. ConMediSys, the developer of safety...

TOPICS:

Gamma-Tocotrienol Kills Prostate Cancer Stem Cells

July 26, 2010 12:33 am | by Bio-Medicine.Org | News | Comments

SINGAPORE , July 25 /PRNewswire-Asia/ -- Scientists from Singapore , Australia and Hong Kong have found that gamma-tocotrienol is potent in killing prostate cancer stem cells. This small group of cells is responsible for the initiation of prostate cancer and is resistant to conventional...

TOPICS:

2008 U.S. Diabetes Drug Delivery - Patient Perspective

July 26, 2010 12:33 am | by Bio-Medicine.Org | News | Comments

NEW YORK , July 26 /- Reportlinker.com announces that a new market research report is available in its catalogue: 2008 U.S. Diabetes Drug Delivery - Patient Perspective http://www.reportlinker.com/p0236248/2008-US-Diabetes-Drug-Delivery---Patient-Perspective.html This...

TOPICS:

San Diego Businesses Receive Health Care Reform Notices From IRS

July 26, 2010 12:32 am | by San Diego Business Journal | News | Comments

One of the first provisions of the Healthcare Reform Act to go into effect may provide relief for many San Diego employers in the form of a small business tax credit designed to assist with the cost of providing health insurance to employees, according to Notice 2010-44 issued by the...

TOPICS:

The Marilyn B. Gula Mountains of Hope Foundation donates additional research funds to TGen

July 26, 2010 12:32 am | by EurekAlert | News | Comments

(The Translational Genomics Research Institute) The Marilyn B. Gula Mountains of Hope Foundation continues its fight against advanced breast cancer with a $50,000 donation to the Phoenix-based Translational Genomics Research Institute (TGen), for a total contribution over two years of $300,000.

TOPICS:

Heart bypass for uncomplicated heart surgery does not reduce neurocognitive function in children

July 25, 2010 9:33 pm | by EurekAlert | News | Comments

(Children's Hospital of Philadelphia) School-aged children who undergo cardiopulmonary bypass during surgery for less complicated congenital heart defects do not appear to suffer any impairments in neurocognitive abilities, such as intelligence, memory, motor skills and behavior....

TOPICS:

Diagnostic 'guidelines' a barrier to prompt relief for some back pain

July 24, 2010 4:34 pm | by EurekAlert | News | Comments

(Johns Hopkins Medical Institutions) Slavishly following long-held guidelines for diagnosing the cause of arthritis-related back pain is resulting in excessive tests, delays in pain relief and wasteful spending of as much as $10,000 per patient, new Johns Hopkins-led research suggests.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading